Financial & Business News
LATEST INVESTING HEADLINES
A Boeing jet intended for use by a Chinese airline landed back at the planemaker's U.S. production hub on Sunday, a victim of the tit-for-tat bilateral tariffs launched by President Donald Trump in his global trade offensive.
UnitedHealth's recent stock drop is an overreaction to Q1 2025 earnings and outlook, presenting a strategic long-term buying opportunity. UNH's strong financials, including increased net income, free cash flow, and dividends, support its resilience and growth potential. Despite negative sentiment and market risks, historical data shows UNH's consistent recovery and higher trading levels after significant drops.
The Macquarie Focused Large Growth ETF offers exposure to 15-25 high-conviction U.S. stocks, aiming to participate in rising markets and weather disruptions. The fund's active managers screen for qualitative and quantitative quality, which is evident based on the portfolio's high net and free cash flow margins. A long-term performance review of Macquarie's large-cap growth mutual fund reveals a strategy of tighter returns: lower highs but higher lows. Its current portfolio beta is also much lower than average.
NEW YORK, NY / ACCESS Newswire / April 19, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=144021&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / April 19, 2025 / If you suffered a loss on your Atkore Inc. (NYSE:ATKR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/atkore-inc-lawsuit-submission-form?prid=144022&wire=1 or contact Joseph E. Levi, Esq.
Smith & Nephew is undergoing a turnaround under CEO Deepak Nath, focusing on margin expansion and growth through surgical robotics and regenerative technologies. Despite trading at a discount to peers, the company shows visible margin improvement, offering a compelling value proposition for investors. The base case projects 35% upside by 2025 with a 20% trading margin, while the bull case suggests 50-60% upside with further margin gains.
NEW YORK, NY / ACCESS Newswire / April 19, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=144020&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / April 19, 2025 / If you suffered a loss on your Ready Capital Corporation (NYSE:RC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ready-capital-corporation-lawsuit-submission-form?prid=144019&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / April 19, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) between October 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period"), of the important May 26, 2025 lead plaintiff deadline. SO WHAT: If you purchased Actinium securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, NY / ACCESS Newswire / April 19, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Atkore Inc. (NYSE:ATKR) between August 2, 2022 and February 3, 2025, both dates inclusive (the "Class Period"), of the important April 23, 2025 lead plaintiff deadline. SO WHAT: If you purchased Atkore common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.